Biogen
BIIB
1,015 hedge funds and large institutions have $59B invested in Biogen in 2017 Q3 according to their latest regulatory filings, with 99 funds opening new positions, 380 increasing their positions, 357 reducing their positions, and 68 closing their positions.
65% more funds holding in top 10
Funds holding in top 10: 23 → 38 (+15)
46% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 68
16% more capital invested
Capital invested by funds: $50.9B → $59B (+$8.14B)
2% more funds holding
Funds holding: 993 → 1,015 (+22)
1.38% more ownership
Funds ownership: 87.81% → 89.19% (+1.4%)
6% more repeat investments, than reductions
Existing positions increased: 380 | Existing positions reduced: 357
22% less call options, than puts
Call options by funds: $980M | Put options by funds: $1.25B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$513M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$310M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$178M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$167M |
| 5 |
Bank of New York Mellon
New York
|
+$133M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$344M |
| 2 |
D.E. Shaw & Co
New York
|
-$206M |
| 3 |
Renaissance Technologies
New York
|
-$190M |
| 4 |
SIG
Senator Investment Group
New York
|
-$136M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$119M |
BIIB Hedge Fund Activity: Q3 2017 in Review
1,015 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2017, worth a combined $59B — up 16% from $50.9B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new BIIB positions and 68 closed out — a net gain of 31 holders — while 380 added to existing stakes and 357 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $513M. The largest seller was BlackRock, cutting an estimated $344M.
- 1,015 institutional investors held Biogen (BIIB) as of Q3 2017, up from 993 in Q2 2017.
- Funds reported $59B of Biogen stock for Q3 2017, up 16% quarter-over-quarter.
- 99 funds opened new Biogen positions in Q3 2017 and 68 closed out, a net change of +31 holders.
- The largest Biogen buyer in Q3 2017 was T. Rowe Price Associates, an estimated $513M added.
- The largest Biogen seller in Q3 2017 was BlackRock, an estimated $344M sold.
Based on aggregated 13F filings for Q3 2017.